EUVIMEDEUVIMED entdecken
Crossref

Four and a half LIM domains 2 (FHL2) attenuates tumorigenesis of gastrointestinal stromal tumors (GISTs) by negatively regulating KIT signaling

Shaoting Zhang, Liangying Zhang, Dan Zhang, Yue Guo, Yisha Gao, Zongying Jiang, Shujing Li, Anbu Liu, Xu Cao, Jinhai Tian, Sien Zhao, Yuanyuan Yu und 6 weitere

Molecular Carcinogenesis · 2024

DOI: 10.1002/mc.23727 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2024. Verfasst von Shaoting Zhang und 17 weiteren Autor:innen. Beteiligte Einrichtung: NHC Key Laboratory of Metabolic Cardiovascular Diseases Research, Science and Technology Center, School of Basic Medical Sciences, Ningxia Medical Un…. Hauptthemen laut MEDLINE: Gastrointestinal Stromal Tumors, Proto-Oncogene Proteins c-kit, LIM-Homeodomain Proteins, Muscle Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Ningxia Province, Research Grants Council of Hong Kong.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastrointestinal stromal tumors (GISTs) are predominately induced by KIT mutants. In this study, we found that four and a half LIM domains 2 (FHL2) was highly expressed in GISTs and KIT signaling dramatically increased FHL2 transcription while FHL2 inhibited KIT transcription. In addition, our results showed that FHL2 associated with KIT and increased the ubiquitination of both wild‐type KIT and primary KIT mutants in GISTs, leading to decreased expression and activation of KIT although primary KIT mutants were less inhibited by FHL2 than wild‐type KIT. In the animal experiments, loss of FHL2 expression in mice carrying germline KIT/V558A mutation which can develop GISTs resulted in increased tumor growth, but increased sensitivity of GISTs to imatinib treatment which is used as the first‐line targeted therapy of GISTs, suggesting that FHL2 plays a role in the response of GISTs to KIT inhibitor. Unlike wild‐type KIT and primary KIT mutants, we further found that FHL2 didn't alter the expression and activation of drug‐resistant secondary KIT mutants. Taken together, our results indicated that FHL2 acts as the negative feedback of KIT signaling in GISTs while primary KIT mutants are less sensitive and secondary KIT mutants are resistant to the inhibition of FHL2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal Stromal TumorsProto-Oncogene Proteins c-kitLIM-Homeodomain ProteinsMuscle ProteinsSignal TransductionTranscription FactorsAnimalsHumansMiceMutationCarcinogenesisGene Expression Regulation, NeoplasticImatinib MesylateGastrointestinal NeoplasmsCell Line, TumorUbiquitination

Stichwörter der Autor:innen

FHL2GISTKITimatinibmutation

Substanzen

Proto-Oncogene Proteins c-kitLIM-Homeodomain ProteinsMuscle ProteinsTranscription FactorsFHL2 protein, humanImatinib MesylateKIT protein, human

Autor:innen und Institutionen

  • NHC Key Laboratory of Metabolic Cardiovascular Diseases Research, Science and Technology Center, School of Basic Medical Sciences, Ningxia Medical University, Yinchuan, China.
  • Key Laboratory for Regenerative Medicine, Ministry of Education, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR, China.
  • Department of Pathology, The First Affiliated Hospital of Naval Military Medical University, Shanghai, China.
  • Department of Emergency, The General Hospital of Ningxia Medical University, Yinchuan, China.
  • Department of Gastroenterology, Ningxia Hospital of Integrated Traditional Chinese and Western Medicine, Yinchuan, China.
  • Department of Laboratory Medicine, Changhai Hospital, Naval Military Medical University, Shanghai, China.

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Ningxia Province
  • Research Grants Council of Hong Kong
  • CAS Center for Excellence in Animal Evolution and Genetics

Zitieren

APA

Zhang, S., Zhang, L., Zhang, D., Guo, Y., Gao, Y., Jiang, Z., Li, S., Liu, A., Cao, X., Tian, J., Zhao, S., Yu, Y., Yang, W., Bai, R., Huang, L., Yan, H., Zhao, H., & Sun, J. (2024). Four and a half LIM domains 2 (FHL2) attenuates tumorigenesis of gastrointestinal stromal tumors (GISTs) by negatively regulating KIT signaling. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23727

Vancouver

Zhang S, Zhang L, Zhang D, Guo Y, Gao Y, Jiang Z, et al. Four and a half LIM domains 2 (FHL2) attenuates tumorigenesis of gastrointestinal stromal tumors (GISTs) by negatively regulating KIT signaling. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23727

BibTeX
@article{Zhang2024,
  author = {Zhang, Shaoting and Zhang, Liangying and Zhang, Dan and Guo, Yue and Gao, Yisha and Jiang, Zongying and Li, Shujing and Liu, Anbu and Cao, Xu and Tian, Jinhai and Zhao, Sien and Yu, Yuanyuan and Yang, Wei and Bai, Ru and Huang, Ling and Yan, Hongli and Zhao, Hui and Sun, Jianmin},
  title = {Four and a half LIM domains 2 (FHL2) attenuates tumorigenesis of gastrointestinal stromal tumors (GISTs) by negatively regulating KIT signaling},
  journal = {Molecular Carcinogenesis},
  year = {2024},
  doi = {10.1002/mc.23727}
}
Kostenlos starten →